Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, UNITED THERAPEUTICS Corp reported revenue of $3.18B, up 10.6% year over year. Operating margin was 46.9% and net margin 41.9%, on a free-cash-flow margin of 32.7% with capital expenditure at 16.4% of revenue. Every figure is computed directly from UTHR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $3.18B | 46.9% | 41.9% |
| FY2024 | $2.88B | 47.9% | 41.5% |
| FY2023 | $2.33B | 50.9% | 42.3% |
| FY2022 | $1.94B | 50.6% | 37.6% |
| FY2021 | $1.69B | 33.0% | 28.2% |
How does UTHR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.